ZURICH/FRANKFURT -Switzerland’s Roche has agreed to pay an initial $7.1 billion to Roivant and Pfizer for rights to a new inflammatory bowel disease drug, as it expands into new fields to offset falling oncology sales. After a succession of production snafus, traders will question whether U.S. aerospace’s “downside youngsters” – Boeing, RTX and Spirit AeroSystems – can stem monetary losses and hit year-end targets. Sign Up NowGet this delivered to your inbox, and more info about our services and products. Emergency services on Spain’s Canary Islands say over 300 migrants have arrived in two boats, bringing to greater than 1,600 …